Diabetes
Adhera Therapeutics Signs Exclusive License Agreement with – GlobeNewswire
Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.) …
Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.) …
/cloudfront-us-east-1.images.arcpublishing.com/gray/Z6CAIIQCWNFMBDC7IM562FY4CA.jpg)